Stamford, US Aug 22, 2025 (Issuewire.com) - Harrison Global Holdings Inc., formerly BloomZ Inc., has signed a strategic international partnership with Biotree Co., Ltd., a Korean biotech pioneer developing the worlds first natural product-based drug for metabolic syndrome.
Why This Matters to Investors
- Biotrees PH-100 has completed Phase 1 trials in the U.S. and Phase 2A trials in Korea, showing strong results in reducing inflammation and improving cardiovascular health.
- The drug is expected to receive conditional approval by mid-2026, opening up prescription-only revenue streams.
- Biotree is the first Korean firm to extract Seapolynol from Gamtae seaweedused in health foods, cosmetics, and pharmaceuticals.
- Harrison Global will help expand Biotrees reach into the U.S., Japan, China, and broader Asia through joint ventures, licensing, and localized development.
Strategic Synergy
This partnership blends Harrisons entertainment and youth engagement expertise with Biotrees biotech innovation, creating a hybrid growth engine across lifestyle, wellness, and media sectors.
Executive Insight
"Were thrilled to contribute to global health by supporting Biotrees breakthrough treatment," said Ryoshin Nakade, Co-CEO of Harrison Global. "This partnership reflects our commitment to innovation and international expansion."
Enrique Vargas
More On Ournewsnation ::
- Andrew Bartnikowski and the Class 12/10/12 Foundation: Supporting Firefighter Families with Strength and Compassion
- Buy Portable 3D Scanner for On-site Inspection — Factory Direct
- How to Choose Top 10 Vacuum Flask Brands Worldwide: A Step-by-Step Quality Control Guide by Skirton
- Addressing Health Trends: Yumart Launches Expanded Line Of Low-Calorie And Gluten-Free Longkou Vermicelli
- Lisa Doverspike on Managing Growth
(845) 288-0020
Source :Harrison Global Holdings
This article was originally published by IssueWire. Read the original article here.